Related Experiment Video

Updated: Aug 19, 2026

Murine Aortic Crush Injury: An Efficient In Vivo Model of Smooth Muscle Cell Proliferation and Endothelial Function
06:14

Murine Aortic Crush Injury: An Efficient In Vivo Model of Smooth Muscle Cell Proliferation and Endothelial Function

Published on: June 11, 2017

Pharmacological neutropenia prevents endothelial dysfunction but not smooth muscle functions impairment induced by

Olivier Pétrault1, Thavarak Ouk, Sophie Gautier

  • 1EA 1046-Laboratoire de Pharmacologie, Institut de Médecine Prédictive et de Recherche Thérapeutique, Université de Lille 2 et Centre Hospitalier Universitaire de Lille, 1 place de Verdun 59045, Lille Cedex, France.

British Journal of Pharmacology
|February 9, 2005
PubMed

Insights

Pharmacological neutropenia, reducing white blood cells, protected brain tissue and blood vessel endothelium in rats after stroke. However, it did not improve smooth muscle function, suggesting a selective protective effect.

Area of Science:

  • Neuroscience
  • Vascular Biology
  • Pharmacology

Background:

  • Polymorphonuclear neutrophils (PMN) contribute to brain damage in acute cerebral infarction.
  • PMN may also cause functional injury to blood vessels post-ischemia.
  • Investigating pharmacological neutropenia's effect on endothelial vs. smooth muscle dysfunction is crucial.

Purpose of the Study:

  • To determine if pharmacological neutropenia modifies post-ischemic endothelial dysfunction.
  • To compare neutropenia's effect on endothelial dysfunction versus smooth muscle dysfunction.
  • To explore the relationship between neuroprotection and endothelial protection by neutropenia.

Main Methods:

  • Cerebral ischemia-reperfusion induced in rats via middle cerebral artery occlusion.
  • Neutropenia achieved using vinblastine or anti-neutrophil antibody (mAb RP-3).
  • Brain infarct volume assessed by histomorphometry; vascular reactivity measured using a myograph.

Main Results:

  • Neutropenia significantly reduced brain infarct size, indicating a neuroprotective effect.
  • Neutropenia prevented the impairment of endothelium-dependent relaxation.
  • Smooth muscle function, including myogenic tone and Kir2.x-dependent relaxation, remained impaired.

Conclusions:

  • Pharmacological neutropenia selectively protects the vascular endothelium, not smooth muscle, post-ischemia.
  • The neuroprotective effect of neutropenia is associated with its endothelial protective action.
  • These findings suggest a link between endothelial protection and reduced brain tissue damage in cerebral infarction.

More Related Videos

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice06:54

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

Published on: June 22, 2022

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Related Concept Videos

Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups: